Ballew Advisors’s Immunogen Inc IMGN Stock Holding History

Ballew Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-200	Closed	-$1K	–	468
2018 Q3	$1K	Buy	+200	New	+$1.92K	﹤0.01%	469

Other funds holding IMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Ballew Advisors's IMGN Position: Q4 2018 in Review

Ballew Advisors sold out of Immunogen Inc (IMGN) in Q4 2018, closing a stake of 200 shares — an estimated $1K sold.

Ballew Advisors first reported a position in IMGN in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 200 funds tracked by Wall St. Rank hold IMGN as of Q4 2018.

Ballew Advisors reported no remaining Immunogen Inc position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 200 Immunogen Inc shares in Q4 2018, an estimated $1K.
Ballew Advisors first reported a position in Immunogen Inc in Q3 2018 and held it in 1 quarter.
Ballew Advisors's Immunogen Inc position peaked at $1K in Q3 2018.
200 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.